Search Results
Your search for The ASCO ,The ASCO matches 21472 pages
Showing 20301 - 20350Multicenter Study Redefines Brain Tumor Diagnosis and Treatment
Scientists at multiple institutions have found a new way of classifying brain cancers that could very well change how the illness is diagnosed and treated. The study, a project of The Cancer Genome Atlas, found striking molecular differences between various forms of gliomas by looking at the makeup ...
Latina Patients With Breast Cancer Need More Culturally Relevant, Language-Specific Stress Management Tools
It is estimated that one of every three Latina women will be diagnosed with cancer during her lifetime. Moffitt Cancer Center researchers, along with collaborators at the University of South Florida, recently published a study about the attitudes and cultural perspectives of Latinas undergoing...
ASCO 2015: IMGN853 Demonstrates Single-Agent Activity for Patients With Platinum-Resistant Ovarian Cancer
In a phase I trial, the investigational agent mirvetuximab soravtansine (IMGN853) was found to be active in patients with platinum-resistant ovarian cancer. ImmunoGen, Inc, announced the first clinical findings of this folate-receptor alpha (FRα)-targeting antibody-drug conjugate at the...
Study Supports Early Intervention for Prostate Cancer Patients Who Experience Significant Emotional Distress
A study led by the University at Buffalo (UB) and Roswell Park Cancer Institute (RPCI) has identified beliefs and personality traits associated with higher levels of distress in patients with newly diagnosed prostate cancer. The findings support the value of emotional and informational support for...
Colorectal Cancer Screening Increase May Reflect Affordable Care Act Provision
Screening for colorectal cancer increased in individuals with a lower socioeconomic status after 2008, perhaps reflecting the Affordable Care Act’s removal of financial barriers to screening, according to a new analysis. The study, by American Cancer Society investigators, was published by...
Study Shows Nearly 15 Million Women Live Prohibitively Far From Access to Gynecologic Cancer Care
More than one-third of counties in the United States are located more than 50 miles from the nearest gynecologic oncologist, making access to specialty care for ovarian and other gynecologic cancers difficult for nearly 15 million women. Although most of these “low-access” counties are...
Analysis Shows Advantage for Picture-Based vs Text-Based Warnings on Cigarette Packs
Pictures illustrating the dangers of cigarette smoking were more effective at strengthening people’s intentions to quit smoking than text warnings, a University of North Carolina at Chapel Hill analysis of multiple research studies has found. These findings were published by Noar et al in...
ASCO 2015: Glioblastoma Poliovirus Therapy Works Best at a Low Dosage
A modified poliovirus therapy that is showing activity in patients with glioblastoma works best at a low dosage, according to the research team at Duke’s Preston Robert Tisch Brain Tumor Center. The dosage findings for the first 20 patients in the phase 1 trial were presented June 1 at the...
Livers Donated After Cardiac Death Are Safe to Use in Liver Cancer Patients
In the largest study of its kind, transplant physicians at Mayo Clinic in Florida have found that liver cancer patients have similar beneficial outcomes whether using organs donated by patients after cardiac death or brain death. The study was recently published by Croome et al in the American...
New Molecular Diagnostic Test Predicts Progression of Barrett's Esophagus to Esophageal Cancer
Interpace Diagnostics, a subsidiary of PDI, Inc, announced new data demonstrating the clinical value of BarreGen, a molecular diagnostic test that predicts the risk of progression from Barrett’s esophagus to esophageal cancer approximately 3 to 4 years before the cancer develops. These...
Palbociclib Improves Progression-Free Survival in Advanced Hormone Receptor–Positive Breast Cancer
In a phase III PALOMA 3 trial reported at the 2015 ASCO Annual Meeting and published in The New England Journal of Medicine, Turner et al found that the cyclin-dependent kinase 4 and 6 inhibitor palbociclib (Ibrance) significantly improved progression-free survival in women with advanced hormone...
Study Examines Nerve Involvement in Cancer Pain
More than half of all cancer patients experience pain, most often associated with the malignancy type, body location, and disease progression. Pain researchers participating in a symposium at the American Pain Society Annual Scientific Meeting last month reported that the relationship between...
Analysis Shows New Cancer Cases Rise Globally, but Death Rates Decline in Many Countries
New cases of virtually all types of cancer are rising in countries globally—regardless of income—but the death rates from cancer are falling in many countries, according to a new analysis of 28 cancer groups in 188 countries. These findings were published by Fitzmaurice et al in JAMA...
Latest RTOG 0537 Data Indicate Electrical Nerve Stimulation May Provide Relief for Radiation-Induced Dry Mouth
Phase III results of Radiation Therapy Oncology Group (RTOG) 0537 indicate that acupuncture-like, transcutaneous electrical nerve stimulation (ALTENS) may be equally effective as the prescription medication pilocarpine, the current standard of care, to treat radiation-induced xerostomia (dry...
Men With Asthma Less Likely to Develop Lethal Prostate Cancer
A recent analysis of a large observational study has revealed that men with a history of asthma are less likely than those without it to develop lethal prostate cancer, researchers at Johns Hopkins reported. These findings were published by Platz et al in the International Journal of Cancer....
ASCO 2015: Patient Misconceptions Persist About Impact of Double Mastectomy on Survival
A University of Michigan survey of women with breast cancer found that nearly half considered having a double mastectomy—but of those who considered it, only 37% knew that the more aggressive procedure does not improve survival for women with breast cancer. Among women who received a double...
ASCO 2015: Study Supports IDH Gene as Prognostic Marker in Anaplastic Astrocytoma
New findings from a phase III clinical trial suggest the IDH1 gene may be a prognostic marker for anaplastic astrocytoma, a rare form of brain cancer. The results of this study were presented on June 2 at the 2015 ASCO Annual Meeting in Chicago (Abstract 2002). Patients in this study who had a...
ASCO 2015: New Targeted Treatment IMMU-130 Shows Activity in Patients With Metastatic Colon Cancer
Although various drugs have improved outcomes for metastatic colon cancer patients, researchers continually strive to find new agents to improve treatment. Antibody-drug conjugates are a promising option, due to the fact that they can deliver chemotherapy directly into a targeted cell, destroy...
ASCO 2015: Biomarker Analysis Reveals Several Potential Treatment Targets in Subtype of Anal Cancer
Squamous cell anal carcinomas are rare, representing only about 2% of gastrointestinal cancer diagnoses. These cancers, which are associated with the human papillomavirus (HPV), sometimes prove very difficult to treat, recurring or developing metastases following standard treatment. Seeking to...
ASCO 2015: First Version of CancerLinQ™ Data Analytics Platform Debuts at Annual Meeting
ASCO’s wholly owned nonprofit subsidiary, CancerLinQ LLC, provided the first demonstration of its groundbreaking health information technology platform at the 2015 ASCO Annual Meeting in Chicago. Beginning May 30, demonstrations of the CancerLinQ platform’s initial components were...
ASCO 2015: Novel Targeted Drug Palbociclib Slows Progression of Hormone Receptor–Positive Breast Cancer
Results from the phase III registration study PALOMA-3 show that adding the investigational targeted agent palbociclib (Ibrance) to the standard hormonal therapy fulvestrant (Faslodex) more than doubled the duration of disease control, delaying disease progression by roughly 5 months in women with...
ASCO 2015: Anastrozole Offers Higher Breast Cancer–Free Interval Rates Than Tamoxifen Following Lumpectomy and Radiation for DCIS
A phase III trial comparing 5 years of tamoxifen vs 5 years of the aromatase inhibitor anastrozole for postmenopausal women treated for ductal carcinoma in situ (DCIS) found 10-year breast cancer–free interval rates were higher in the anastrozole group than in the tamoxifen group (93.5% vs...
ASCO 2015: Entolimod May Be a Promising Treatment Option for Many Solid Tumors
A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute, shared results from the first clinical study of the anticancer effects of the novel agent entolimod on May 30 at the 2015 ASCO Annual Meeting in Chicago (Abstract 3063). Their findings confirm ...
ASCO 2015: Economic Costs a Burden for Cancer Survivors
A new study conducted by the American Cancer Society found that the economic burden of cancer extends beyond diagnosis and treatment, with cancer survivors facing thousands of dollars of excess medical expenses every year, as well as excess employment disability and loss of production at work. The...
ASCO 2015: NCI-MATCH Trial Links Targeted Drugs to Genetic Abnormalities
Investigators for the nationwide trial NCI-MATCH: Molecular Analysis for Therapy Choice announced at the 2015 ASCO Annual Meeting in Chicago that the precision medicine trial will open to patient enrollment in July. The trial seeks to determine whether targeted therapies for people whose tumors...
ASCO 2015: Eribulin Extends Overall Survival for Heavily Pretreated Patients With Advanced Liposarcoma and Leiomyosarcoma
Heavily pretreated patients with intermediate- or high-grade liposarcoma or leiomyosarcoma had a 2-month increase in median overall survival when subsequently treated with eribulin (Halaven) rather than the standard drug dacarbazine. “For a disease where so few treatment options exist, a...
ASCO 2015: Investigational ALK Inhibitor Demonstrates Promising Overall Response Rates in Patients With Advanced ALK-Positive NSCLC
The oral investigational anaplastic lymphoma kinase (ALK) inhibitor alectinib shrank tumors in almost half of patients with advanced ALK-positive non–small cell lung cancer (NSCLC) whose disease had progressed following crizotinib (Xalkori) treatment. Positive results from two clinical...
ASCO 2015: ASCO Announces First-Ever Clinical Trial
ASCO announced its first-ever clinical trial, which will offer patients with advanced cancer access to molecularly targeted cancer drugs and collect “real-world” data on clinical outcomes, to help learn the best uses of these drugs outside of indications approved by the U.S. Food and...
ASCO 2015: Complete Lymph Node Dissection Does Not Improve Survival in Patients With Melanoma and Micrometastases
For patients with melanoma and micrometastases, as shown by positive sentinel lymph node biopsy, complete lymph node dissection did not improve survival, according to results of a randomized study presented at the 2015 ASCO Annual Meeting (Abstract LBA9002). “This is the first study which...
ASCO 2015: Phase III Study Confirms Benefits of Lenalidomide Maintenance Therapy for Patients With Multiple Myeloma
A large, cooperative group study directed by the Alliance for Clinical Trials in Oncology has confirmed previous evidence that the drug lenalidomide (Revlimid) delays time to disease progression for patients with multiple myeloma and is an important treatment option for patients with this rare but...
ASCO 2015: First Effective Adjuvant Chemotherapy for High-Risk, Localized Prostate Cancer
“For the first time, improvement in overall survival was observed with tolerable adjuvant chemotherapy for localized, high-risk prostate cancer,” Howard Sandler, MD, Professor of Radiation Oncology at Cedars-Sinai Medical Center in Los Angeles, announced at a press briefing at the...
ASCO 2015: Tumor Sequencing Study Highlights Benefits of Profiling Healthy Tissue
As the practice of genetically profiling patient tumors for clinical treatment decision-making becomes more commonplace, a recent study from The University of Texas MD Anderson Cancer Center suggests that profiling normal DNA also provides an important opportunity to identify inherited mutations...
ASCO 2015: For Patients With Limited Brain Metastases, Adjuvant Whole-Brain Radiation Therapy Increases Cognitive Decline Without Improving Survival
A federally funded phase III trial found that adding whole-brain radiation therapy to radiosurgery did not significantly extend survival of patients with one to three small metastases of the brain, although it did help to control the growth of brain metastases, as evidenced by imaging studies....
ASCO 2015: Elective Neck Dissection Improves Early Oral Cancer Survival
A randomized phase III study resolves long-standing questions about the optimal timing of neck lymph node surgery for patients with early-stage oral cancer by showing that elective neck dissection both improves survival and lowers recurrence rates compared to therapeutic neck dissection performed...
ASCO 2015: Reduction in Late Mortality Among Childhood Cancer Survivors Linked to Improvements in Cancer Care
Survivors of childhood cancer in recent eras have shown a significant reduction in late mortality, and “for the first time, we have been able to attribute that to fewer deaths from treatment-related causes or fewer deaths from late effects of the primary therapy,” Gregory T....
ASCO 2015: Discussing Child’s Cancer Prognosis Beneficial for Parents
New findings by researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center show that informing parents about their child’s cancer prognosis—even when the prognosis is less than favorable—is much more likely to give parents peace of mind and hope, rather...
ASCO 2015: Second-Line Afatinib Improves Overall Survival vs Erlotinib in Advanced Squamous Cell Carcinoma of the Lung
In a phase III head-to-head trial comparing the safety and efficacy of two EGFR-directed treatments, afatinib (Gilotrif) treatment resulted in a significant improvement in overall survival over erlotinib (Tarceva) in patients with previously treated advanced squamous cell carcinoma of the lung....
ASCO 2015: Phase III Study Finds Nivolumab Improves Progression-Free Survival, Especially When Combined With Ipilimumab, in Advanced Melanoma
A randomized phase III trial among patients with previously untreated melanoma found that initial therapy with nivolumab (Opdivo) alone more than doubled the median progression-free survival compared with ipilimumab (Yervoy) alone (6.9 vs 2.9 months), and the benefit was even greater when the two...
ASCO 2015: Removing More Breast Tissue Reduces by Half the Need for Second Cancer Surgery
Removing more tissue during a partial mastectomy could spare thousands of breast cancer patients a second surgery, according to a Yale Cancer Center study. The findings were presented May 30 at the 2015 ASCO Annual Meeting (Abstract 1012) in Chicago and simultaneously published by Chagpar ...
ASCO 2015: Variations in Liver Cancer Attributable to Hepatitis Virus Variations
Significant clinical variations exist among patients with the most common type of liver cancer, hepatocellular carcinoma, depending on the viral cause of the disease—hepatitis B virus (HBV) or hepatitis C virus (HCV). These differences suggest that hepatitis status should be considered when...
ASCO 2015: JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis
Findings from the PERSIST-1 study of patients with myelofibrosis show that the JAK inhibitor pacritinib is significantly more effective than best available therapy, which includes a range of off-label treatments, for easing the symptoms of myelofibrosis. At a landmark analysis at 24 weeks of...
ASCO 2015: First-in-Class Targeted Drug Daratumumab Is Effective as Single Agent in Heavily Treated Multiple Myeloma
“Daratumumab monotherapy produced unprecedented overall responses that deepened over time” in a phase II trial among patients with heavily treated multiple myeloma, study author Saad Zafar Usmani, MD, reported at a press conference at the 2015 ASCO Annual Meeting. Dr. Usmani, a...
ASCO 2015: New Ibrutinib Combination Regimen Shows Substantial Benefits in Relapsed Chronic Lymphocytic Leukemia
First results from a randomized phase III study show that the combination of ibrutinib (Imbruvica) and bendamustine (Treanda)/rituximab (Rituxan) improves outcomes for patients with chronic lymphocytic leukemia (CLL) that progressed despite prior therapy. At a median follow-up of 17 months,...
ASCO 2015: Obinutuzumab Doubles Progression-Free Survival in Patients With Relapsed, Indolent Non-Hodgkin Lymphoma
Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard bendamustine (Treanda) chemotherapy and then following that with single-agent obinutuzumab maintenance therapy “resulted in a statistically significant, but more importantly, a clinically meaningful increase in...
ASCO 2015: Bevacizumab Combination Boosts Survival in Advanced Stomach and Esophageal Cancers
Patients whose metastatic stomach or esophageal cancers were driven by a mutated HER2 gene had markedly improved response rates and survival when bevacizumab (Avastin) was added to a standard drug combination. Scientists at Dana-Farber Cancer Institute, who led the research, will report these...
ASCO 2015: Melanoma Rates Dramatically Increasing in Children and Young Adults
The incidence of melanoma has increased by more than 250% among children, adolescents, and young adults since 1973, according to research to be presented by Roswell Park Cancer Institute (RPCI) on June 1 at the 2015 ASCO Annual Meeting (Abstract 9058) in Chicago. The research has been recognized...
ASCO 2015: Colorectal Cancer Genetically Different in Older and Younger Patients
Although the overall rate of colorectal cancer is declining, colorectal cancer specifically among young patients is increasing. Previous studies have shown that colorectal cancer in patients younger than 50 years old tends to be more aggressive than in older patients. A University of Colorado (CU)...
ASCO 2015: Study Clarifies Best Treatments for Non–Clear Cell Kidney Cancers
A head-to-head comparison of two biologic therapies used to treat a subset of patients with advanced kidney cancers provides much-needed clarity on the preferred method of first-line treatment. The phase II ASPEN trial, led by researchers at the Duke Cancer Institute, is the first and largest trial ...
ASCO 2015: Pembrolizumab Produces Clinically Meaningful Response in Patients With Recurrent or Metastatic Head and Neck Cancer
Immunotherapy with pembrolizumab (Keytruda) produced a clinically meaningful overall response rate in a study among 132 patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The overall objective response rate was 24.8%, and 57% of patients experienced some tumor...
ASCO 2015: Nivolumab Extends Survival for Patients With Nonsquamous Non–Small Cell Lung Cancer
Superior overall survival was experienced by patients receiving the anti–PD-1 antibody nivolumab (Opdivo) in a randomized phase III study of patients with nonsquamous non–small cell lung cancer (NSCLC) whose disease progressed after a platinum-based doublet chemotherapy. Study...
